Atherosclerosis Clinical Trials

Find Atherosclerosis Clinical Trials Near You

The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension: A Substudy of Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Background: Hypertension (HT) is the most common condition worldwide, predisposing to atherosclerotic disease. However, most HT patients have suboptimal BP control despite anti-HT medications. Isometric resistance exercise (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contraction with minimal change in muscle length and joint angle. Most randomized trials of IRE are short duration and their long-term effects on BP and atherosclerotic complications, particularly in the Chinese, remain unknown. Study objectives: (i) To evaluate the impact of IRE on atherogenesis surrogates (brachial flow-mediated dilation, FMD and carotid intima-media thickness IMT). (ii) To evaluate the impact of IRE on mechanisms of atherogenesis improvement, inflammatory parameters, arterial wall stiffness (cfPWV) and biochemical profiles. Setting: Randomized samples of 200 HT patients, aged \>18years with systolic BP 135-160mHg while on no or stable anti-HT medications.

Design: Randomized controlled IRE trial - stratified randomization with randomization block size of 4. 1. 100 patients for wall squat exercise of 14 mins each session (2 mins IRE x 4 sets, 2 mins rest in between), 3 sessions per week, for 1 year, plus advice on healthy diet and lifestyle. 2. 100 control patients (usual care) with advice on diet and healthy lifestyles and simple stretching exercise programme for 1 year. All patients will be invited to continue their exercise programme and return for follow up FMD and carotid IMT at 24 weeks and 1 year, and PWV at 24 weeks. Main outcome measures: 1. Brachial FMD and carotid IMT at baseline, 24 weeks and 1 year. (primary outcome) 2. Carotid-femoral pulse wave velocity (cf-PWV) at baseline and 24 weeks. (secondary outcome) 3. Important atherosclerosis risk factor parameters at baseline, 24 weeks and 1 year - including fasting serum glucose, lipid profiles, HgbA1-C, creatinine, hs-CRP, CBP, fibrinogen, and interleukin 6 (IL-6). (secondary outcome) 4. Safety profiles (if any) including CVS event and hospitalization at 1 year. Expected results: IRE Intervention versus control group, (i) 3mHg more reduction in SBP (Clinic and AMBP). (ii) A group absolute difference in FMD of 1%, and in carotid IMT of 0.06mm between the 2 treatment groups. Implications: IRE as suggested will be beneficial to management of HT, and will be of great importance in health care of this common disorder in both primary and secondary preventions of atherosclerosis diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• asymptomatic clinically stable adults

• aged \>18 years

• Both genders

• Suboptimal BP (on stable medication) with SBP 135-160mmHG on ambulatory BP monitoring (AMBP)

• Agreeable to no drug changes in coming 1 year 24 weeks

• Agreeable to provide informed written consent form

• Agreeable to have AMBP and ultrasonic (FMD \& IMT) scan third (baseline, 24 weeks and preferably 1 year)

Locations
Other Locations
Hong Kong Special Administrative Region
The Chinese University of Hong Kong, Department of Medicine & Therapeutics
RECRUITING
Shatin
Contact Information
Primary
KS Woo, MBBS, MD, FACC
kamsangwoo@cuhk.edu.hk
+852 26474966
Time Frame
Start Date: 2025-04-16
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 200
Treatments
Active_comparator: Anti HT + Isometric Resistance Squatting Exercise (100 Adults)
A more linear thigh-leg squatting angle is allowed in initial 2 weeks, but aiming at 90 degree thigh-leg angle after 4 weeks.
Active_comparator: Anti HT + Stretching Exercise (100 Adults)
A liberal leg stretching excerise will be practised
Related Therapeutic Areas
Sponsors
Leads: Chinese University of Hong Kong

This content was sourced from clinicaltrials.gov